Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study
- PMID: 19926670
- PMCID: PMC2789587
- DOI: 10.1093/rheumatology/kep352
Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study
Abstract
Objective: Inflammatory arthritis in childhood is variable in terms of both presentation and outcome. This analysis describes disease activity in children with juvenile idiopathic arthritis (JIA) during the first year following presentation to a paediatric rheumatologist and identifies predictors of moderate to severe disability [defined using a Childhood HAQ (CHAQ) score >or=0.75] at 1 year.
Methods: The Childhood Arthritis Prospective Study recruits children <16 years with new inflammatory arthritis persisting for >or=2 weeks from five UK tertiary referral centres. Demographics, disease features, joint count, CHAQ, physician's global assessment, parent's general evaluation of well-being (PGE), ESR and treatment, are collected at first presentation, 6 months and then yearly. Independent predictors of CHAQ >or=0.75 at 1 year in children diagnosed with JIA were identified using multivariable logistic regression models.
Results: Seven hundred and forty children with JIA were included; median age at presentation 7.6 years, 64% girls. During the first year, 85% received NSAIDs, 70% IA corticosteroids, 47% MTX and 27% systemic steroids (oral or i.v.). Median presenting CHAQ score was 0.63 and decreased to 0.25 at 1 year; 32% had CHAQ >or=0.75 at 1 year. The strongest predictor of CHAQ >or=0.75 at 1 year was CHAQ >or=0.75 at presentation (odds ratio 3.92; 95% CI 2.17, 7.09). Additional predictors included female gender and higher PGE.
Conclusion: Although CHAQ score improved in most children, the strongest predictor of persistent disability at 1 year was moderate to severe disability at first presentation. Follow-up beyond 1 year will assess whether CHAQ at presentation will continue to be a predictor of future poor outcome.
Similar articles
-
The correlation between the Childhood Health Assessment Questionnaire and disease activity in juvenile idiopathic arthritis.Musculoskeletal Care. 2018 Sep;16(3):339-344. doi: 10.1002/msc.1239. Epub 2018 Mar 24. Musculoskeletal Care. 2018. PMID: 29573557
-
Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study.Rheumatology (Oxford). 2008 Jul;47(7):991-5. doi: 10.1093/rheumatology/ken085. Epub 2008 Apr 16. Rheumatology (Oxford). 2008. PMID: 18417527 Free PMC article.
-
Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.Health Technol Assess. 2019 Apr;23(15):1-140. doi: 10.3310/hta23150. Health Technol Assess. 2019. PMID: 31033434 Free PMC article. Clinical Trial.
-
Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis.Joint Bone Spine. 2002 Oct;69(5):468-81. doi: 10.1016/s1297-319x(02)00432-3. Joint Bone Spine. 2002. PMID: 12477231
-
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial.Ann Rheum Dis. 2010 Aug;69(8):1479-83. doi: 10.1136/ard.2009.120840. Epub 2010 Jun 4. Ann Rheum Dis. 2010. PMID: 20525842 Clinical Trial.
Cited by
-
Single-cell RNA sequencing in juvenile idiopathic arthritis.Genes Dis. 2023 May 24;11(2):633-644. doi: 10.1016/j.gendis.2023.04.014. eCollection 2024 Mar. Genes Dis. 2023. PMID: 37692495 Free PMC article. Review.
-
Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.J Rheumatol. 2012 Sep;39(9):1867-74. doi: 10.3899/jrheum.120110. Epub 2012 Aug 1. J Rheumatol. 2012. PMID: 22859354 Free PMC article.
-
Ultrasonography and color Doppler in juvenile idiopathic arthritis: diagnosis and follow-up of ultrasound-guided steroid injection in the wrist region. A descriptive interventional study.Pediatr Rheumatol Online J. 2012 Apr 21;10:11. doi: 10.1186/1546-0096-10-11. Pediatr Rheumatol Online J. 2012. PMID: 22520244 Free PMC article.
-
Functional status of Indian children with juvenile idiopathic arthritis.Rheumatol Immunol Res. 2024 Jul 15;5(2):126-129. doi: 10.1515/rir-2024-0016. eCollection 2024 Jun. Rheumatol Immunol Res. 2024. PMID: 39015846 Free PMC article.
-
Toxoplasma and Toxocara seropositivity in juvenile idiopathic arthritis and its relation to disease activity and type of therapies.Food Waterborne Parasitol. 2023 May 19;31:e00195. doi: 10.1016/j.fawpar.2023.e00195. eCollection 2023 Jun. Food Waterborne Parasitol. 2023. PMID: 37256200 Free PMC article.
References
-
- Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol. 1996;23:1975–80. - PubMed
-
- Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29:1989–99. - PubMed
-
- Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. J Am Med Assoc. 2005;294:1671–84. - PubMed
-
- Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48:767–75. - PubMed
-
- Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology. 2002;41:1428–35. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous